Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state

Aurore Thibaut, Sarah Wannez, Anne-Francoise Donneau, Camille Chatelle, Olivia Gosseries, Marie-Aurélie Bruno & Steven Laureys

To cite this article: Aurore Thibaut, Sarah Wannez, Anne-Francoise Donneau, Camille Chatelle, Olivia Gosseries, Marie-Aurélie Bruno & Steven Laureys (2017): Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state, Brain Injury, DOI: 10.1080/02699052.2016.1274776

To link to this article: http://dx.doi.org/10.1080/02699052.2016.1274776

Published online: 10 Mar 2017.

Submit your article to this journal

View related articles

View Crossmark data
Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state

Aurore Thibaut, Sarah Wannez, Anne-Francoise Donneau, Camille Chatelle, Olivia Gossieres, Marie-Aurélie Bruno, and Steven Laureys

Original Article

ABSTRACT

Objectives: To assess the effects of repeated transcranial direct current stimulation (tDCS) sessions on the level of consciousness in chronic patients in minimally conscious state (MCS).

Methods: In this randomized double-blind sham-controlled crossover study, we enrolled 16 patients in chronic MCS. For 5 consecutive days, each patient received active or sham tDCS over the left prefrontal cortex (2 mA during 20 min). Consciousness was assessed with the Coma Recovery Scale-Revised (CRS-R) before the first stimulation (baseline), after each stimulation (day 1–day 5) and 1 week after the end of each session (day 12).

Results: A treatment effect ($p = 0.013$; effect size = 0.43) was observed at the end of the active tDCS session (day 5) as well as 1 week after the end of the active tDCS session (day 12; $p = 0.002$; effect size = 0.57). A longitudinal increase of the CRS-R total score was identified for the active tDCS session ($p < 0.001$), while no change was found for the sham session ($p = 0.64$). Nine patients were identified as responders (56%).

Conclusion: Our results suggest that repeated (5 days) left prefrontal tDCS improves the recovery of consciousness in some chronic patients in MCS, up to 1 week after the end of the stimulations.

Introduction

Transcranial direct current stimulation (tDCS) delivers a weak (usually 1–2 mA) electrical current through the brain using two electrodes, an anode and a cathode placed on the scalp [1]. It is presumed that anodal tDCS strengthens synaptic connections through a mechanism similar to long-term potentiation, while cathodal tDCS seems to have an opposite effect [2,3]. Better performances were observed on working memory tasks during and after active tDCS over the left dorsolateral prefrontal cortex (DLPFC) in healthy volunteers and in patients with stroke, suffering from Parkinson’s disease, and moderate traumatic brain injury [4–7]. Similarly, tDCS over the left DLPFC seems to have positive effects on attention in patients with stroke [8] and in patients with mild [9] or severe [10] traumatic brain injury suffering from attentional deficits.

We recently reported an improvement in the level of consciousness in patients with disorders of consciousness (DOC), especially patients in a minimally conscious state (MCS; showing reproducible but inconsistent signs of consciousness [11,12]), following a single session of DFPLC tDCS [13]. This finding is noteworthy as there are very few evidence-based guidelines regarding the treatment of patients with DOC [14,15]. Until now, only amantadine has been shown to increase the pace of recovery of patients with severe traumatic brain injury in a subacute population (4–16 weeks post-injury [16]). However, if amantadine enhances the pace of recovery in subacute stage, it may not be as efficient at improving the level of consciousness in patients in a chronic stage [15]. Additionally, amantadine is associated with side effects such as epileptic seizure [17] and may, therefore, not always be supported by the patient [18]. tDCS has been widely studied, and there is no severe side effect when applied within the safety criteria [19]. In this context, tDCS has the advantage to have little to no side effects, even when the stimulations are repeated daily [20,21].

As the effects of a single tDCS stimulation on patients with DOC seem to last a few hours, we here aim to determine whether these short-term effects can be amplified and made more durable by the use of repeated stimulations. Indeed, previous studies on stroke patients or patients with Parkinson disease showed that repeating the number of stimulations (e.g., 5 or 10 days) could increase the duration of the effect from 1 week to 1 month [22–24]. Similarly, Angelakis et al. investigated in a prospective case series trial, the effect of repeated tDCS over the left DLPFC or the primary motor cortex in 7 chronic patients in unresponsive wakefulness syndrome (UWS—i.e., eyes opened, but no awareness of self or environment [25,26]) and three patients in MCS [27]. No behavioural changes were observed in patients in UWS, while the three patients in MCS demonstrated clinical improvement. However, among the patients in MCS, only one received tDCS over the prefrontal cortex. Therefore, in a double-blind randomized sham-controlled crossover study, we assessed the effects of daily sessions of tDCS over the left DLPFC on the level...
of consciousness in chronic patients in MCS. We hypothesized that repeated tDCS over the left DLPFC (i.e., 5 consecutive days of stimulation), as compared to sham stimulations, will improve the level of consciousness (as measured by changes in CRS-R total scores) in a sample of chronic patients in MCS. We focused on chronic patients (>3 months post-insult [13]) to avoid the spontaneous recovery period, which could be a confounding factor. Our second hypothesis is that the effects will last at least 1 week after the end of the active tDCS session, and that these effects will linearly increase over the 5 days of stimulation. Finally, we hypothesized that the number of responders to repeated tDCS sessions will increase as compared to our first study (i.e., single stimulation).

**Methods**

**Patients**

We prospectively enrolled medically stable patients in chronic MCS between January 2011 and August 2014. The sample size was based on the duration of the ethic committee approval (i.e., 4 years).

Inclusion criteria were: (1) being in MCS according to the published diagnosis criteria; (2) more than 3 months post-injury; (3) acquired traumatic or non-traumatic etiology [11]. We excluded patients with unclear diagnosis during prescreening assessments and patients with a metallic cerebral implant or pacemaker (in line with the safety criteria for tDCS in human subjects [17]). Patients were studied free of sedative drugs and Na+ or Ca++ channel blockers (e.g., carbamazepine) or NMDA receptor blockers (e.g., dextromethorphan) to avoid interaction with the presumed neuromodulatory effects of tDCS [28]. We did not include patients with a cranioplasty. Medications (two patients were on amantadine) and rehabilitation (e.g., number of sessions per week and type of therapy performed by physical therapists, occupational therapists, and speech therapists or any other type of therapy such as hydrotherapy) were kept unchanged throughout the experiment. If the medication and/or rehabilitation were modified during the protocol, the patients had to be excluded from the study, as well as if two consecutive assessments were missing due to clinical purposes (e.g., nursing or physical therapy cares needed). Clinically, we defined as responders the patients who showed at least one new sign of consciousness (e.g., response to command, visual pursuit, objects recognition or localization, automatic motor reaction, localization of noxious stimuli or intentional communication) during the 5 days of tDCS, and who kept displaying this behaviour 1 week later, as compared to baseline and sham stimulation.

**Materials**

Each patient received both active and sham DLFPC tDCS sessions in a randomized order. A computer-generated randomization sequence was used to assign in a 1:1 ratio the first session as active tDCS or sham stimulation. For the sham session, the employed tDCS device (Neuroconn DC Stimulator Plus, NeuroConn GmbH, Ilmenau, Germany) offers a built-in placebo mode, which is activated by an anonymous code number and includes ramp periods of 5 s at the beginning and the end of sham stimulation to mimic the somatosensory artefact of active tDCS. Two investigators were involved in data collection. The same investigator performed both tDCS and CRS-R assessments on the same patient. For each patient, the experimenter received two blinded codes from a third person, one for the active stimulation and one for the sham stimulation. Thus, active and sham tDCS could not be identified either by the blinded experimenters who administered tDCS and CRS-R, or by the patients.

Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 × 5 cm) with the anode positioned over the left DLPF cortex (F3 according to the 10–20 international system for EEG placement [29]) and the cathode placed over the right supraorbital region, as previously described [30]. During tDCS, the current was ramping up to 2 mA (in 5 s) from the onset of stimulation and applied for 20 min. For the sham condition, the same electrode placement was used as in the active condition, but the current was applied for 5 s only, and was then ramped down to 0 mA. Impedances were kept <10 kΩ and voltage <26 V.

tDCS was performed daily, at the same time of the day, for 5 consecutive days. tDCS and sham stimulations were tested in a random order in two different block sessions separated by 1 week of washout (as published elsewhere [31]—see Figure 1).

tDCS treatment effect was assessed by means of standardized CRS-R assessments performed by two trained and experienced blinded experimenters [32]. The CRS-R consists of 23 hierarchically arranged items (from reflexes—e.g., visual or auditory startle; to more complex voluntary behaviours—e.g., command following, visual pursuit, object manipulation, recognition or localization) comprising six subscales assessing auditory, visual, motor, verbal, communication and arousal functions. Diagnosis is based on the presence or absence of specific behavioural responses to sensory stimuli administered in a standardized manner as described in the guidelines [32]. The lowest item on

---

**Figure 1.** Protocol of the study. CRS-R, Coma Recovery Scale-Revised; tDCS, transcranial direct current stimulation; BL, baseline; d, day. Active and sham tDCS sessions were randomized.
each subscale represents reflexive activity, whereas the highest items represent cognitively mediated behaviours. Before inclusion in this study, each patient was assessed at least 4 times during a 1-week period in order to establish a clear diagnosis. For the protocol, CRS-R assessments were performed directly before the first baseline session and after each active tDCS and sham sessions as well as 1 week later.

Side effects were evaluated by the experimenters after each stimulation and included (1) the presence of redness of the skin under the electrodes; (2) signs of discomfort, as assessed by observation of the facial expression (e.g., grimace or tears [11,33,34]); and (3) arousal CRS-R subscale (to assess any possible sedative effect).

**Standard protocol approvals, registrations and patient consents**

Written informed consents were obtained by the legal representative of each patient. The study was approved by the ethics committee of the University and University Hospital of Liège, Belgium (ClinicalTrials.gov NCT02019615).

**Statistics**

Statistical analysis was performed using SAS (version 9.3 for Windows) statistical package. The effect of the treatment was analysed based on the modification of the CRS-R total score. The differences considered in the present study were: [day 5—baseline] and [day 12—baseline]. In each situation, the individual data recorded during the crossover study were analysed according to the method described elsewhere [35] and summarized hereafter. At the group level, we first looked for a period, interaction and treatment effect. The period effect refers to the calculation of active tDCS-sham stimulation response differences, which were then compared according to the order of administration using a Mann-Whitney U test. The interaction effect referred to the calculation of the mean response after active tDCS and sham session, which was then compared according to the period using a Mann-Whitney U test. If no period and interaction effect was found, then treatment effect was assessed using a Wilcoxon match-paired signed-rank test. Results were considered significant at \( p < 0.05 \). Multiple comparisons using Bonferroni correction (six comparisons) had to be performed for the secondary end-point assessment (i.e., assessment of CRS-R subscale change according to tDCS/sham), and results were considered significant at \( p < 0.0083 \) (i.e., 0.05/6). To evaluate the longitudinal evolution of the CRS-R score between treatment groups, a mixed model with an undefined covariance structure was fitted to the data. The covariates included in the model were the time and the interaction with the treatment indicator. This statistical method allows the comparison of response curves between treatments while accounting for dependency of the data within each patient. The effect size was calculated using the following expression \( r = z/\sqrt{2n} \) where \( z \) is the statistics obtained from the Wilcoxon signed-rank test [36]. Results were considered significant at the 5% critical level (\( p < 0.05 \)). Differences between responders and non-responders were assessed using a t-test (i.e., age and time since insult) and a chi-square test (i.e., aetiology).

**Results**

We assigned 21 eligible patients to receive both active and sham tDCS in a crossover study design. Two patients were excluded from the study after the first washout period because of medical complications that required a modification of medication (one patient had a pulmonary infection and the other had epileptic seizures). Three other patients were also excluded from the study due to missing CRS-R assessments for 2 consecutive days (i.e., incomplete, missing or delayed—more than 1 h)—CRS-R assessments due to nursing cares or physical therapy cares for pulmonary congestion, needed after the stimulation session—see Figure 2). The five drop-outs did not differ from the others in terms of age (\( p = 0.443 \)), time since injury (\( p = 0.515 \)) or baseline CRS-R (\( p = 0.669 \)).

Sixteen patients completed the study (mean age of 47 [17–74] years; 9 men; interval since insult: 85 [5–365] months; 11 post-traumatic, 5 non-traumatic—i.e., anoxic and stroke). Demographic data are reported in Table I. Nine patients first received active tDCS, and seven patients first received sham stimulation. There was no significant clinical or demographic difference between the 2 groups. We did not identify any period or interaction effect (\( p > 0.05 \)), at day 5 nor at day 12. At the group level, a difference was observed between the two treatment conditions at day 5 (\( p = 0.013 \)) as well as 1 week after the last stimulation (day 12 \( p = 0.002 \) (Figure 3)).

![Figure 2. Study flowchart.](image-url)
Table I. Demographic data and coma recovery scale-revised scores.

<table>
<thead>
<tr>
<th>ID</th>
<th>Age (sex)</th>
<th>Etiology</th>
<th>Structural brain lesions (MRI or CT)</th>
<th>Time since insult (months)</th>
<th>Session</th>
<th>Baseline CRS-R</th>
<th>Post d1 CRS-R</th>
<th>Post d2 CRS-R</th>
<th>Post d3 CRS-R</th>
<th>Post d4 CRS-R</th>
<th>Post d5 CRS-R</th>
<th>Post d12 CRS-R</th>
<th>Delta baseline</th>
<th>Delta baseline—day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>17 (M)</td>
<td>TBI</td>
<td>Frontal and temporal, diffuse cortical atrophy</td>
<td>21</td>
<td>Sham</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>9</td>
<td>6</td>
<td>-2</td>
<td>12</td>
</tr>
<tr>
<td>2*</td>
<td>32 (F)</td>
<td>TBI</td>
<td>Bilateral frontal and moderate diffuse cortical atrophy, Right fronto-parietal craniotomy.</td>
<td>75</td>
<td>Anodal</td>
<td>6</td>
<td>4</td>
<td>6</td>
<td>11</td>
<td>11</td>
<td>9</td>
<td>5</td>
<td>4</td>
<td>-1</td>
</tr>
<tr>
<td>3*</td>
<td>74 (F)</td>
<td>Anoxic stroke</td>
<td>Bilateral moderate diffuse cortical atrophy</td>
<td>11</td>
<td>Sham</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>7</td>
<td>6</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>-1</td>
</tr>
<tr>
<td>4</td>
<td>35 (M)</td>
<td>TBI</td>
<td>Bilateral moderate diffuse cortical atrophy</td>
<td>54</td>
<td>Anodal</td>
<td>6</td>
<td>8</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>5*</td>
<td>50 (M)</td>
<td>TBI</td>
<td>Moderate right fronto-temporal cortical atrophy.</td>
<td>88</td>
<td>Sham</td>
<td>13</td>
<td>13</td>
<td>10</td>
<td>9</td>
<td>14</td>
<td>13</td>
<td>13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>40 (M)</td>
<td>TBI</td>
<td>Right posterior lesion.</td>
<td>243</td>
<td>Sham</td>
<td>11</td>
<td>12</td>
<td>14</td>
<td>15</td>
<td>13</td>
<td>12</td>
<td>13</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>31 (F)</td>
<td>TBI</td>
<td>Bilateral temporo-parietal diffuse cortical atrophy.</td>
<td>20</td>
<td>Anodal</td>
<td>8</td>
<td>6</td>
<td>6</td>
<td>8</td>
<td>9</td>
<td>7</td>
<td>9</td>
<td>-1</td>
<td>-1</td>
</tr>
<tr>
<td>8</td>
<td>56 (F)</td>
<td>TBI</td>
<td>Frontal and temporal, diffuse cortical atrophy (L&gt;R). Left parietal craniotomy</td>
<td>20</td>
<td>Sham</td>
<td>14</td>
<td>14</td>
<td>15</td>
<td>14</td>
<td>15</td>
<td>14</td>
<td>15</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>9*</td>
<td>65 (F)</td>
<td>CA</td>
<td>Bilateral severe diffuse cortical atrophy</td>
<td>5</td>
<td>Sham</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>49 (F)</td>
<td>CA</td>
<td>Bilateral moderate diffuse cortical atrophy (L&gt;R)</td>
<td>15</td>
<td>Anodal</td>
<td>5</td>
<td>6</td>
<td>8</td>
<td>5</td>
<td>7</td>
<td>9</td>
<td>9</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>11*</td>
<td>54 (F)</td>
<td>TBI</td>
<td>Right fronto-temporo-parietal cortical atrophy</td>
<td>21</td>
<td>Sham</td>
<td>13</td>
<td>13</td>
<td>14</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>12*</td>
<td>35 (M)</td>
<td>CA</td>
<td>Bilateral severe diffuse cortical atrophy</td>
<td>146</td>
<td>Anodal</td>
<td>8</td>
<td>8</td>
<td>11</td>
<td>9</td>
<td>10</td>
<td>13</td>
<td>13</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>13*</td>
<td>29 (M)</td>
<td>TBI</td>
<td>Left fronto-temporo-occipital cortical atrophy</td>
<td>134</td>
<td>Anodal</td>
<td>13</td>
<td>15</td>
<td>18</td>
<td>19</td>
<td>18</td>
<td>19</td>
<td>19</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>25 (M)</td>
<td>TBI</td>
<td>Bilateral moderate cortical atrophy</td>
<td>17</td>
<td>Sham</td>
<td>8</td>
<td>11</td>
<td>12</td>
<td>11</td>
<td>8</td>
<td>9</td>
<td>8</td>
<td>0</td>
<td>-1</td>
</tr>
<tr>
<td>15</td>
<td>59 (M)</td>
<td>Anoxic stroke</td>
<td>Right occipital cortical atrophy.</td>
<td>17</td>
<td>Anodal</td>
<td>8</td>
<td>8</td>
<td>14</td>
<td>8</td>
<td>14</td>
<td>8</td>
<td>8</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>16*</td>
<td>42 (M)</td>
<td>TBI</td>
<td>Moderate left temporal-parietal cortical atrophy</td>
<td>365</td>
<td>Sham</td>
<td>11</td>
<td>12</td>
<td>9</td>
<td>14</td>
<td>13</td>
<td>12</td>
<td>12</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Demographic data and coma recovery scale-revised (CRS-R) total scores of patients during anodal tDCS and sham tDCS sessions. TBI, traumatic brain injury; CA, cardiac arrest; *responder, *patient previously diagnosed as MCS but UWS for the first CRS-R.

We did not observe any significant effect of tDCS on any of the six CRS-R subscales.

When we looked at the longitudinal change of the CRS-R scores, an improvement of the CRS-R total scores was found for the active tDCS session across time ($p < 0.001$), while no change was observed under the sham session ($p = 0.64$, Figure 4).

At the individual level, 9 of the 16 patients were identified as tDCS responders (i.e., patients who demonstrated a new sign of consciousness). The recovery of signs of consciousness included response to command, recognition and localization of objects, motor response and visual fixation/pursuit. Functional communication, which is a criterion of the emergence of MCS [11], was also observed in two patients after active tDCS. Behavioural improvements for tDCS responders are detailed in Table II. Four patients responded after the first stimulation session (i.e., 25%, which is similar to the 23% observed in our first study [13]). The other 5 responders improved behaviourally after 2 ($n = 2$), 3 ($n = 1$) or 4 days ($n = 2$) of tDCS. When comparing demographic data of responders and non-responders, we did not identify any difference in terms of age ($p = 0.788$), time since insult ($p = 0.683$) or aetiology ($p = 0.930$).

No side effect was observed after any of the stimulation. Four patients, however, showed redness of the skin following both active and sham tDCS stimulation, but it disappeared within 30 min. We did not find any difference for the arousal subscales before and after the stimulation sessions. No patient showed signs of discomfort. No seizures occurred during the stimulation sessions, even in patients treated for epilepsy.

**Discussion**

We identified a positive effect of repeated tDCS over the left DLPFC on level of consciousness in chronic patients in MCS. In addition, these effects lasted at least 1 week after the last stimulation. Our results are in line with previous studies, reporting a positive short lasting effect (1 or 2 h) of tDCS on cognition [5,6,37,38] as well as the longer lasting effect (from 1 week up to 1 month) associated with repeated stimulations, in pain [39], stroke [23,40] and Parkinson disease [22].

As mentioned in the introduction, a previous case series study reported clinical improvement in 10 chronic (>6 months) patients with DOC after repeated tDCS over the left DLPFC ($n = 5$) or the primary motor ($n = 5$) cortices [27]. The only patient in MCS who received tDCS over the left DLPFC cortex showed a behavioural improvement characterized by the recovery of pain localization. However, the reappearance of this particular...
behaviour was not observed in our cohort of 9 responders who presented various new signs of consciousness.

When we looked at the longitudinal changes on the CRS-R scores, we observed a significant increase over time (from day 1 to 12). In addition, we observed an increase in the effect size when comparing the first (single) stimulation (i.e., 0.38) [13] to the fifth one (i.e., 0.43). The effect size also increased at day 12 (i.e., 1 week after the end of the stimulation—0.57), suggesting that 5-day stimulation increases the duration and the strength of tDCS clinical effects.

Some authors hypothesized that repeating tDCS every day could improve corticocortical excitability and therefore, strengthen the effect of the stimulation [39]. One study showed that tDCS induced greater motor evoked potential amplitude in healthy subjects when delivered every day rather than every other day [41]. This could reflect superior cumulative effects between stimulation rather than a greater response to each individual tDCS [41]. These studies are in line with our observation, since we identified an increased number of responders with the number of stimulations, together with an increased duration of the effect, lasting up to 1 week after the last stimulation.

Another study investigating the effect of tDCS (over the primary motor cortex) on human consciousness in REM sleep, demonstrated that tDCS could influence motor imagery during this stage of sleep [42]. The authors also suggested that, since REM sleep is involved in motor development and the preparation of movements, tDCS could be used to stimulate motor function, and especially in patients who suffered from immobilization, such as severely brain-injured patients with DOC, highlighting another potential benefit of tDCS for the rehabilitation of patients with DOC.

In our previous trial using a single stimulation, we observed that 43% of MCS (in both acute and chronic stage) was responsive to tDCS [13]. However, when looking at the chronic MCS, only 23% responded to tDCS. In the present study, we noticed that 25% (n = 4) of our sample responded after the first stimulation, which is similar to our previous results. Interestingly, we observed that five other patients showed improvement after 2, 3 or even 4 days of stimulation, resulting in 56% of responders after 5 days of stimulation. These results suggest that repeating tDCS daily could increase the number of responders, and that the first session is not
predictive of a future positive effect of the stimulation on the level of consciousness.

The increased effects of tDCS over the sessions could be due to an increase in NMDA receptor excitability, which could improve and strengthen cortical excitability within the stimulated area [1,2]. More distant areas also seem to be involved in tDCS responsiveness. For patients in MCS, we recently identified that responders to a single session of tDCS showed more grey matter preservation and residual metabolic activity, as compared to non-responders, in the stimulated area (i.e., left DLPFC), in the precuneus, and in the thalamus; areas known to be involved in conscious processes [43]. These results suggest that not only the stimulated area but also areas implicated in consciousness are involved in the mechanisms of action and clinical effects of tDCS in patients with severe brain injured and DOC [44]. However, the stimulated area and the consciousness network need to remain at least partially preserved. Recently, another study also showed that tDCS could be used as a diagnostic tool to disentangle patients in MCS from UWS [45]. The authors identified that active tDCS induced an increase in cortical connectivity and excitability (measured by transcranial magnetic stimulations) in patients in MCS, while improvement was only observed in patients clinically diagnosed with UWS who showed recovery to MCS at follow-up. This study showed that beside the treatment effect of tDCS, this technique could be useful to detect residual connectivity markers in clinically UWS patients who may recover behavioural signs of consciousness later on.

As supported by our findings and previous studies, it is well known that tDCS is a low-risk technique [19,46]. In the 16 patients who completed the study, no seizure or sign of potential pain (e.g., grimace, tears) was observed. No complication related to the protocol occurred during the active tDCS or the sham sessions. Four patients had moderate redness of the skin that disappeared within 30 min. tDCS did not have any effect on the level of arousal on any of the patients. Those observations

**Table II. List of CRS-R responses recovered following tDCS in the 9 responders.**

<table>
<thead>
<tr>
<th>Items</th>
<th>Detailed responses during the CRS-R assessment</th>
<th>Number of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic command following</td>
<td>4 out of 4 responses at “move your right arm”</td>
<td>1</td>
</tr>
<tr>
<td>Reproducible command following</td>
<td>3 out of 4 responses at “move your right hand/fingers”</td>
<td>1</td>
</tr>
<tr>
<td>Sound localization*</td>
<td>Turn head when presenting the own name behind the head of the patient at least twice</td>
<td>1</td>
</tr>
<tr>
<td>Object recognition</td>
<td>Recognize a comb and/or a cup, visually on 3 or more occasions</td>
<td>2</td>
</tr>
<tr>
<td>Automatic motor reaction</td>
<td>Spontaneous motor reaction (i.e., grab bed sheet)</td>
<td>1</td>
</tr>
<tr>
<td>Visual pursuit</td>
<td>Follow mirror on at least 2 occasions in the same direction</td>
<td>2</td>
</tr>
<tr>
<td>Visual fixation</td>
<td>Fixate a ball on at least 2 occasions</td>
<td>1</td>
</tr>
<tr>
<td>Object localization</td>
<td>Reaching ball with the hand on demand at 3 occasions</td>
<td>1</td>
</tr>
<tr>
<td>Functional communication**</td>
<td>Accurately respond to 6 autobiographical yes/no questions (e.g., is your name Patrick, do you have 32 years old, is your father’s name Christopher)</td>
<td>2</td>
</tr>
</tbody>
</table>

CRS-R, coma recovery scale-revised.
*Does not denotes MCS.
**Denotes EMCS if observed on two consecutive assessments.

**Table III. CONSORT 2010 checklist of information to include when reporting a randomised trial**.

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>Item No</th>
<th>Checklist item</th>
<th>Reported on page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title and abstract</td>
<td>1a</td>
<td>Identification as a randomised trial in the title</td>
<td>P1</td>
</tr>
<tr>
<td></td>
<td>1b</td>
<td>Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)</td>
<td>P1</td>
</tr>
<tr>
<td>Introduction</td>
<td>2a</td>
<td>Scientific background and explanation of rationale</td>
<td>P3–4</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>Specific objectives or hypotheses</td>
<td>P4</td>
</tr>
<tr>
<td>Methods</td>
<td>3a</td>
<td>Description of trial design (such as parallel, factorial) including allocation ratio</td>
<td>P6–7</td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</td>
<td>P9</td>
</tr>
<tr>
<td>Participants</td>
<td>4a</td>
<td>Eligibility criteria for participants</td>
<td>P5</td>
</tr>
<tr>
<td></td>
<td>4b</td>
<td>Settings and locations where the data were collected</td>
<td>P5</td>
</tr>
<tr>
<td>Interventions</td>
<td>5</td>
<td>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</td>
<td>P6</td>
</tr>
<tr>
<td>Outcomes</td>
<td>6a</td>
<td>Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed</td>
<td>P6–7</td>
</tr>
<tr>
<td></td>
<td>6b</td>
<td>Any changes to trial outcomes after the trial commenced, with reasons</td>
<td>/</td>
</tr>
<tr>
<td>Sample size</td>
<td>7a</td>
<td>How sample size was determined</td>
<td>P5</td>
</tr>
<tr>
<td></td>
<td>7b</td>
<td>When applicable, explanation of any interim analyses and stopping guidelines</td>
<td>/</td>
</tr>
<tr>
<td>Randomisation: Sequence generation</td>
<td>8a</td>
<td>Method used to generate the random allocation sequence</td>
<td>P5</td>
</tr>
<tr>
<td></td>
<td>8b</td>
<td>Type of randomisation; details of any restriction (such as blocking and block size)</td>
<td>P5</td>
</tr>
<tr>
<td>Allocation concealment mechanism</td>
<td>9</td>
<td>Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned</td>
<td>P5–6</td>
</tr>
<tr>
<td>Implementation</td>
<td>10</td>
<td>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</td>
<td>P6</td>
</tr>
<tr>
<td>Blinding</td>
<td>11a</td>
<td>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</td>
<td>P6</td>
</tr>
<tr>
<td></td>
<td>11b</td>
<td>If relevant, description of the similarity of interventions</td>
<td>P6</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>12a</td>
<td>Statistical methods used to compare groups for primary and secondary outcomes</td>
<td>P8</td>
</tr>
<tr>
<td></td>
<td>12b</td>
<td>Methods for additional analyses, such as subgroup analyses and adjusted analyses</td>
<td>P8</td>
</tr>
</tbody>
</table>

(Continued)
suggest that tDCS may be applied safely in daily clinical practice. Nevertheless, further studies need to be performed to assess the long-term effect (e.g., 1, 3, and 6 months) of repeated tDCS in patients with severe brain injury.

The observed positive effects coupled with the absence of adverse events, make tDCS an interesting tool that could be implemented in rehabilitation settings. In addition, it is relatively inexpensive and easy to use. Therefore, the use of tDCS in patients with severe brain injury during the rehabilitation program could improve or fasten their recovery. New studies investigating the effect of long-term protocol (e.g., 4 weeks of stimulation) should be performed in order to evaluate the feasibility of a clinical translation of tDCS. In addition, several studies have shown that tDCS coupled with a specific therapy could enhance its effects [47,48]. Therefore, combining tDCS with other therapies, such as physical therapy or occupational therapy, in patients with DOC should be tested as well.

Our study has several limitations. Firstly, we only performed one follow-up assessment after 1 week. It would thus be useful in future tDCS studies to conduct follow-up testing at longer intervals to determine whether treatment effects can last more than 1 week after treatment. In addition, even if the interaction effect was not statistically significant, there is a trend towards a carry-over effect. Therefore, future clinical trials using tDCS should include a longer washout period. Another limitation is the smaller sample of patients included. We were not able to recruit more than 21 patients for this protocol during a 4-year period. Therefore, multicentric and international studies will be necessary to replicate and confirm the results in a larger population of patients.

In conclusion, tDCS applied over the left prefrontal cortex seems to be safe and can enhance the level of consciousness in some chronic patients in MCS. Moreover, the effects appeared to last at least 1 week after the end of the stimulations. In addition, the first session was not predictive of a future positive effect of tDCS on the level of consciousness as the number of responders doubled after 5 days of tDCS as compared with the first day of stimulation. Even though our findings are based on a small sample size, these preliminary results strongly support the need to further investigate the use of tDCS as a therapeutic intervention in patients with DOC.

Acknowledgments

The authors thank Pr. Gustave Moonen, Pr. Pierre Maquet, the Neurology Department staff of the University Hospital of Liège, the ISOSL Rehabilitation Center, Centre d’Accueil de Bouge, the Foyer Saint-Anne, the University of Liège, the Duesberg Foundation, the Belgian American Educational Foundation, the Wallonie-Bruxelles International, the James McDonnell Foundation, Mind Science Foundation, IAP research network P7/06 of the Belgian Government (Belgian Science Policy), the European Commission, Human Brain Project (EU-H2020-fetflagship-hbp-sga1-ga720270), and Luminus project (EU-H2020-fetopen-ga686764). AT and OG are post-doctoral fellows, and SL is research director at FRS-FNRS.

Funding

Funding was provided by: European Commission, James S McDonnell Foundation, Belgian National Fund for Scientific Research (FNRS), Concerted Research Action, the Belgian American Educational Foundation (BAEF), the Fédération Wallonie Bruxelles International (WBI), the Massachusetts General Hospital Department of Neurology and Division of Neurocritical Care and Emergency Neurology, and the
University of Wisconsin-Madison. The source of the funding of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

SL is Research Director at FNRS, OG is post-doctoral fellows at FNRS.

Authorship

AT and SL designed the protocol. AT and MAB obtained the data. AT, SW and SL interpreted data and wrote the manuscript. SW and AFD analysed the data. CC and OG contributed to the writing of the manuscript. All authors were involved in editing the paper and approved the final text.

Declaration of interest

The authors report no conflicts of interest.

References


42. Speth J, Speth C. Motor imagery in REM sleep is increased by transcranial direct current stimulation of the left motor cortex (C3). Neuropsychologia 2016;86:57–65.


